Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 17/20 | 0.45 |
| ▸ | CA1 | P00915 | 12/20 | 0.45 |
| ▸ | CA9 | Q16790 | 8/20 | 0.45 |
| ▸ | CA12 | O43570 | 4/20 | 0.43 |
| ▸ | CA7 | P43166 | 4/20 | 0.43 |
| ▸ | CA14 | Q9ULX7 | 4/20 | 0.43 |
| ▸ | CA3 | P07451 | 2/20 | 0.43 |
| ▸ | CA4 | P22748 | 2/20 | 0.43 |
| ▸ | CA6 | P23280 | 2/20 | 0.43 |
| ▸ | CA5A | P35218 | 2/20 | 0.43 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.43 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.41 |
| ▸ | LAP3 | P28838 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL28419791 | 0.98 | TP53 (0.45) | TP53CA2CA1CA9CA12 | |
| Hydrochloric Acid SCHEMBL28418644 | 0.98 | TP53 (0.45) | TP53CA2CA1CA9CA12 | |
| SCHEMBL1487360 | 0.98 | CA2 (0.47) | TP53CA2CA1CA9CA12 | |
| SCHEMBL19028602 | 0.98 | CA2 (0.47) | TP53CA2CA1CA9CA12 | |
| SCHEMBL28486619 | 0.98 | CA2 (0.47) | TP53CA2CA1CA9CA12 | |
| Hydrochloric Acid SCHEMBL28210759 | 0.96 | CA2 (0.46) | TP53CA2CA1CA9CA12 | |
| SCHEMBL277861 | 0.93 | CA2 (0.45) | CA2CA1CA9CA12CA7 | |
| SCHEMBL24665746 | 0.88 | CA2 (0.50) | TP53CA2CA1CA9CA12 | |
| SCHEMBL20542290 | 0.88 | CA2 (0.50) | TP53CA2CA1CA9CA12 | |
| SCHEMBL7109060 | 0.88 | CA2 (0.50) | TP53CA2CA1CA9CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112119076-B | Spiropiperidine allosteric modulators of nicotinic acetylcholine receptors | 默沙东有限责任公司 | 2025-01-10 | — | — | CN | claimed |
| EP-3788043-A1 | SPIROPIPERIDINE ALLOSTERIC MODULATORS OF NICOTINIC ACETYLCHOLINE RECEPTORS | Merck Sharp & Dohme Corp. (US) | 2021-03-10 | — | — | EP | claimed |
| CN-112119076-A | Spiropiperidine allosteric modulators of nicotinic acetylcholine receptors | 默沙东公司 | 2020-12-22 | — | — | CN | claimed |
| US-20250115591-A1 | NOVEL SULFONAMIDE CARBOXAMIDE COMPOUNDS | INFLAZOME LTD (IE) | 2025-04-10 | — | — | US | disclosed |
| EP-3788043-B1 | SPIROPIPERIDINE ALLOSTERIC MODULATORS OF NICOTINIC ACETYLCHOLINE RECEPTORS | MERCK SHARP & DOHME LLC (US) | 2024-11-06 | — | — | EP | disclosed |
| CN-112204008-B | Sulfonylaminobenzamides and sulfonylaminobenzamide derivatives | 奥索生物公司 | 2024-07-05 | — | — | CN | disclosed |
| US-20230037255-A1 | NOVEL SULFONAMIDE CARBOXAMIDE COMPOUNDS | INFLAZOME LTD (IE) | 2023-02-02 | — | — | US | disclosed |
| EP-3788043-A1 | SPIROPIPERIDINE ALLOSTERIC MODULATORS OF NICOTINIC ACETYLCHOLINE RECEPTORS | Merck Sharp & Dohme Corp. (US) | 2021-03-10 | — | — | EP | disclosed |
| CN-112204008-A | Sulphonylaminobenzylamide and sulphonylaminobenzamide derivatives | 吉利德科学公司 | 2021-01-08 | — | — | CN | disclosed |
| CN-112119076-A | Spiropiperidine allosteric modulators of nicotinic acetylcholine receptors | 默沙东公司 | 2020-12-22 | — | — | CN | disclosed |
| CN-110914256-A | Novel sulfonamide carboxamide compounds | 英夫拉索姆有限公司 | 2020-03-24 | — | — | CN | disclosed |
| EP-2228435-A1 | METHOD FOR AMPLIFICATION OF HEMATOPOIETIC STEM CELL USING HETEROCYCLIC COMPOUND | Nissan Chemical Industries, Ltd. (JP) | 2010-09-15 | — | — | EP | disclosed |
| EP-2218716-A1 | METHOD FOR AMPLIFYING HEMATOPOIETIC STEM CELLS USING HETEROCYCLIC COMPOUND | Nissan Chemical Industries, Ltd. (JP) | 2010-08-18 | — | — | EP | disclosed |
| US-20090253751-A1 | HYDRAZIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2009-10-08 | — | — | US | disclosed |
| US-20090198060-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2009-08-06 | — | — | US | disclosed |
| US-20090131659-A1 | AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2009-05-21 | — | — | US | disclosed |
| EP-2025671-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR | Nissan Chemical Industries, Ltd. (JP) | 2009-02-18 | — | — | EP | disclosed |
| EP-1947101-A1 | HYDRAZIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR | Nissan Chemical Industries, Ltd. (JP) | 2008-07-23 | — | — | EP | disclosed |
| EP-1845090-A1 | AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR | Nissan Chemical Industries, Ltd. (JP) | 2007-10-17 | — | — | EP | disclosed |
| CN-1146565-C | Polymorphs of citrate salts of crystalline azabicyclo [2,2,2] octan-3-amine derivatives and pharmaceutical compositions thereof | �Ʒ� | 2004-04-21 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131659-A1 | AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR | TEK, PTAFR, MPL | TP53 1466/4885CA2 3065/4885CA1 2999/4885 |
| US-20090198060-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR | TEK, MPL, IL1RN | TP53 1094/4885CA2 2806/4885CA1 2865/4885 |
| US-20090253751-A1 | HYDRAZIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR | TEK, THPO, PTAFR | TP53 1646/4885CA2 1765/4885CA1 2064/4885 |
| US-20250115591-A1 | NOVEL SULFONAMIDE CARBOXAMIDE COMPOUNDS | NLRP3, NOD1, NLRP1 | TP53 1591/4885CA2 1431/4885CA1 3091/4885 |
| US-20230037255-A1 | NOVEL SULFONAMIDE CARBOXAMIDE COMPOUNDS | NLRP3, NOD1, NLRP1 | TP53 1739/4885CA2 1368/4885CA1 2915/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.